Tag: Europe
-
Grants for Orphan Disease Academic-Industry Partnerships
The Wellcome Trust in the U.K. has unveiled new funding for academic-industry partnerships in early-stage research and development projects targeting orphan and neglected diseases. The Pathfinder Awards aim to encourage pilot research projects with potential for developing new products that address diseases affecting a small percentage of the population (orphan diseases) or conditions that that…
-
Merck, Biopharm to Partner on Hypoxia-Targeting Cancer Drug
Threshold Pharmaceuticals Inc., a biopharmaceutical company in South San Francisco, California and Merck KGaA, the global drug manufacturer in Darmstadt, Germany have agreed to co-develop and commercialize Threshold’s drug TH-302. The drug TH-302 targets hypoxia, caused by low oxygen levels due to insufficient blood vessel growth, a common condition of tissues with many solid tumors,…
-
Manchester to Host U.K. Graphene Research Institute
The Engineering and Physical Sciences Research Council (EPSRC) in the U.K. confirmed today that University of Manchester will host the U.K.’s national graphene institute, a facility for graphene research and commercialization activities planned for use by both scientists and businesses. University of Manchester is the home of Sir Andre Geim and Sir Kostya Novoselov, who…
-
Pharmas, Foundations, Agencies Partner on Tropical Diseases
In London yesterday, the Bill & Melinda Gates Foundation, 13 pharmaceutical companies, three governments, the World Bank and global health agencies announced a new plan to eliminate or control 10 neglected tropical diseases (NTDs) by 2020. The effort announced at an event at the Royal College of Physicians is aimed at 1.4 billion people living…
-
FDA Approves Genentech Skin Cancer Drug
The Food and Drug Administration today approved the drug vismodegib to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug, marketed under the brand name Erivedge by Genentech in South San Francisco, is intended for use in patients with locally advanced basal cell cancer who are not candidates…
-
Nanotech Paint Devised to Monitor for Structural Damage
Researcher engineers at University of Strathclyde in Glasgow, U.K. have developed a type of paint that can help detect early signs of structural damage in bridges or buildings. Because this “smart paint” can be applied like any other paint and requires little maintenance, it costs a small fraction of traditional instrument-based sensors. Strathclyde civil engineering…
-
Venture Investment for European Companies Drops in 2011
Venture capital declined 14 percent and number of deals dropped 19 percent for European companies in 2011 compared to 2010, with €4.4 billion ($US 5.8 billion) going into 1,012 deals. Industries based on scientific discoveries were among those suffering double-digit percentage declines from the previous year. Dow Jones VentureSource that compiled the data says it…
-
Dutch Biotech Raises $30M for Rare Disease Therapies
Prosensa, a biopharmaceutical company in Leiden, the Netherlands, says it has raised €23 million ($30 million) in new equity financing. The company develops therapeutics using ribonucleic acid (RNA) modulation to address rare diseases, including Duchenne muscular dystrophy, myotonic dystrophy, and Huntington’s disease. The funding round is led by New Enterprise Associates in Menlo Park, California,…
-
Soap Developed with Magnetic Properties
Researchers at University of Bristol in the U.K. and Institut Laue-Langevin in Grenoble, France have developed a soap with iron salts that can be controlled by magnets. The discovery is expected to lead to products useful in cleaning up oil spills at sea, which can be better captured and removed after use than currently available…
-
Process IDs Rice Traits to Help Tsunami-Hit Rice Growers
A collaboration between scientists in Japan and the U.K. is developing methods to identify genetic markers that can help cut the time needed to breed salt-tolerant and shorter rice to help Japanese growers recover from the tsunami in March 2011. The new process, called MutMap, is described online in the journal Nature Biotechnology (paid subscription…